News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Private CNS Company Review for 2010 Released by NI Research


1/20/2010 1:09:22 PM

CARDIFF, CA--(Marketwire - January 20, 2010) -

NI Research, the publisher of NeuroInvestment, has released the 2010 edition of the Private CNS Company Review. The completely revised and updated 2010 edition provides a unique database of information about the private companies specializing in the development of novel therapeutics for neurological/psychiatric disorders.

For each of the 102 companies covered, PCNS describes and appraises scientific platforms; clinical/preclinical activity; contact information; alliances; financing; prospects, and licensing opportunities. Licensing and M&A opportunities are also compiled and appraised, as are rosters of company funding and VC financing. NI Research has published PCNS since 2003, and it has become a highly valued Business Development tool for the neuropharm industry.

Table of Contents for PCNS 2010:
Introduction and Comment
Private Company Fates/Casualties  2003-9
Private CNS Company Funding 2009
Scavenger Hunt
PCNS Licensing Opportunities by Stage
Top PCNS Licensing Opportunities
Top PCNS M&A Opportunities
Accera/Neuera
AC Immune
Acumen  Pharmaceuticals
Adamas Pharmaceuticals
Affectis Pharmaceuticals
Affiris
Afraxis
AgeneBio
Alzhyme
American Life Science Pharmaceuticals
Archer Pharmaceuticals
Arcion Therapeutics
ArmaGen Technologies
AurimMed Pharma
Axon-Neuroscience
Axxonis Pharma AG
Azevan Pharmaceuticals
Bayhill Therapeutics
BioArctic Neuroscience
BioChromix Pharma
BrainCells
BrainTact
Cambria Pharmaceuticals
Cara Therapeutics
Cellzome
CeNeRx BioPharma
Ceregene
Clera
Cognition Pharmaceuticals
Cognition Therapeutics
Cognosci
CoLucid
CoMentis
Embera Neurotherapeutics
ENKAM Pharmaceuticals
EnVivo Pharmaceuticals
Galantos Pharma
Galenea
GliaMed
Helicon Therapeutics/
Dart Neuroscience
Intra-Cellular Therapies
KeyNeurotek
Kinexis
Knopp Neurosciences
Link Medicine
Maas Biolab
Medeia Therapeutics
MedGenesis
MediProPharma
Mithridion
M's Science
Neuraltus
NeurAxon
Neureva
Neurim
Neurimmune
NeuroGeneration
NeuroHealing
NeuroKos
Neuronascent
NeuroNova
NeuroProtect
NeuroTherapeutics Pharma
Neurotune AG
NoNO Inc.
Noscira
NsGene
NuPathe
Oligomerix
PharmaNeuroBoost
Pharmaxon
Pharnext
Probiodrug
ProMentis Pharmaceuticals
Proneuron Biotechnologies
Proteostasis Therapeutics
Psyadon Pharmaceuticals
Psylin Neuroscience
Q Therapeutics
RemeGenix
SanBio
Satori Pharmaceuticals
SCT Spinal Cord Therapeutics
Seaside Therapeutics
Senexis
Solace Pharmaceuticals
Solstice Neurosciences
Sonexa Therapeutics
Spinifex
Stealth Peptides
Synosia Therapeutics
TauRx
TauTaTis
TheraQuest Biosciences
to-BBB
Trophos
Xenome Ltd
Yaupon Therapeutics
Zenobia
Zogenix
Programs by Company, Indication, Stage
Company Funding
VC Funding Roster

NI Research is the leading publisher of independent research on the neurotherapeutics industry. NI Research has published NeuroInvestment since 1995; the Private CNS Company Review since 2003; and CNS Disorders/Therapeutics since 2007. NI Research also provides licensing consultation and research for large and small pharmaceutical firms. NI Research has developed an unmatched information base regarding both publicly and privately-held neuro-oriented companies.

To download PCNS 2010 information/order form: http://www.niresearch.com/PCNS 2010 order.pdf


Contact:
NI Research
P.O. Box 1028
Cardiff CA 92007
760.230.2581
E-mail: Email Contact
Websites: www.niresearch.com
www.neuroinvestment.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES